Abstract：
UNASSIGNED: This retrospective, single-center, case-control study evaluated the safety and efficacy of Computed tomography (CT)-guided microwave ablation (MWA) for pulmonary nodules located in the right middle lobe (RML), a challenging location associated with a high frequency of complications.
UNASSIGNED: Between May 2020 and April 2022, 71 patients with 71 RML pulmonary nodules underwent 71 MWA sessions. To comparison, 142 patients with 142 pulmonary nodules in non-RML were selected using propensity score matching. The technical success, technique efficacy, complications, and associated factors were analyzed. The duration of the procedure and post-ablation hospital stay were also recorded.
UNASSIGNED: Technical success was achieved in 100% of all patients. There were no significant differences in technique efficacy rates between the RML and non-RML groups (97.2% vs. 95.1%, p = 0.721). However, both major (47.9% vs. 19.7%, p < 0.001) and minor (26.8% vs. 11.3%, p = 0.004) pneumothorax were more common in the RML group than non-RML group. MWA for RML pulmonary nodules was identified as an independent risk factor for pneumothorax (p < 0.001). The duration of procedures (51.7 min vs. 35.3 min, p < 0.001) and post-ablation hospital stays (4.7 days vs. 2.8 days, p < 0.001) were longer in the RML group than non-RML group.
UNASSIGNED: CT-guided MWA for RML pulmonary nodules showed comparable efficacy compared with other lobes, but posed a higher risk of pneumothorax complications, necessitating longer MWA procedure times and extended hospital stays.
UNASSIGNED: Between May 2020 and April 2022, 71 patients with 71 RML pulmonary nodules underwent 71 MWA sessions. To comparison, 142 patients with 142 pulmonary nodules in non-RML were selected using propensity score matching. The technical success, technique efficacy, complications, and associated factors were analyzed. The duration of the procedure and post-ablation hospital stay were also recorded.
UNASSIGNED: Technical success was achieved in 100% of all patients. There were no significant differences in technique efficacy rates between the RML and non-RML groups (97.2% vs. 95.1%, p = 0.721). However, both major (47.9% vs. 19.7%, p < 0.001) and minor (26.8% vs. 11.3%, p = 0.004) pneumothorax were more common in the RML group than non-RML group. MWA for RML pulmonary nodules was identified as an independent risk factor for pneumothorax (p < 0.001). The duration of procedures (51.7 min vs. 35.3 min, p < 0.001) and post-ablation hospital stays (4.7 days vs. 2.8 days, p < 0.001) were longer in the RML group than non-RML group.
UNASSIGNED: CT-guided MWA for RML pulmonary nodules showed comparable efficacy compared with other lobes, but posed a higher risk of pneumothorax complications, necessitating longer MWA procedure times and extended hospital stays.
摘要：
■这次回顾，单中心,病例对照研究评估了计算机断层扫描（CT）引导下微波消融（MWA）治疗右中叶（RML）肺结节的安全性和有效性，一个具有挑战性的位置与高频率的并发症。
■在2020年5月至2022年4月期间，71例RML肺结节患者接受了71次MWA治疗。为了比较，使用倾向评分匹配选择了142例非RML中142例肺结节的患者。技术上的成功,技术功效，并发症,并对相关因素进行分析。还记录了手术时间和消融后住院时间。
■100%的患者获得了技术成功。RML组和非RML组之间的技术有效率没有显着差异（97.2％vs.95.1%,p=0.721）。然而,两者都是主要的(47.9%与19.7%,p<0.001）和次要（26.8%与11.3%,p=0.004）气胸在RML组比非RML组更常见。RML肺结节的MWA被确定为气胸的独立危险因素(p<0.001)。手术持续时间(51.7分钟vs.35.3分钟,p<0.001)和消融后住院时间(4.7天vs.2.8天,p<0.001）在RML组比非RML组更长。
■CT引导的MWA治疗RML肺结节的疗效与其他肺叶相当，但是气胸并发症的风险更高，需要更长的MWA手术时间和延长的住院时间。
■在2020年5月至2022年4月期间，71例RML肺结节患者接受了71次MWA治疗。为了比较，使用倾向评分匹配选择了142例非RML中142例肺结节的患者。技术上的成功,技术功效，并发症,并对相关因素进行分析。还记录了手术时间和消融后住院时间。
■100%的患者获得了技术成功。RML组和非RML组之间的技术有效率没有显着差异（97.2％vs.95.1%,p=0.721）。然而,两者都是主要的(47.9%与19.7%,p<0.001）和次要（26.8%与11.3%,p=0.004）气胸在RML组比非RML组更常见。RML肺结节的MWA被确定为气胸的独立危险因素(p<0.001)。手术持续时间(51.7分钟vs.35.3分钟,p<0.001)和消融后住院时间(4.7天vs.2.8天,p<0.001）在RML组比非RML组更长。
■CT引导的MWA治疗RML肺结节的疗效与其他肺叶相当，但是气胸并发症的风险更高，需要更长的MWA手术时间和延长的住院时间。
